Rexulti, Rxulti(brexpiprazole)
Brexpiprazole, Rexulti, Rxulti (brexpiprazole) is a small molecule pharmaceutical. Brexpiprazole was first approved as Rexulti on 2015-07-10. It is used to treat major depressive disorder, schizophrenia, and schizophrenia spectrum and other psychotic disorders in the USA. It has been approved in Europe to treat schizophrenia. It is known to target D(2) dopamine receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| mental disorders | D001523 |
Trade Name
FDA
EMA
Brexpiprazole, Rexulti (discontinued: Brexpiprazole)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| brexpiprazole | ANDA | 2025-06-27 |
| rexulti | New Drug Application | 2025-06-18 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
BREXPIPRAZOLE, REXULTI, OTSUKA | |||
| 2026-05-10 | I-913 | ||
| 2024-12-27 | NPP | ||
HCPCS
No data
Clinical
Clinical Trials
97 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Schizophrenia | D012559 | EFO_0000692 | F20 | 10 | 3 | 16 | 1 | 1 | 30 |
| Depression | D003863 | — | F33.9 | 1 | 4 | 15 | 3 | 1 | 23 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | 1 | 4 | 15 | 3 | 1 | 23 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 1 | 4 | 15 | 2 | — | 21 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | 1 | — | 3 | 1 | — | 5 |
| Psychotic disorders | D011618 | — | F20.81 | 1 | — | — | 1 | 1 | 3 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mental disorders | D001523 | EFO_0000677 | F91.9 | 1 | — | 7 | — | 1 | 9 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | 1 | 6 | — | 2 | 8 |
| Dementia | D003704 | EFO_0003862 | F03 | — | 1 | 5 | — | 2 | 7 |
| Psychomotor agitation | D011595 | — | — | — | 1 | 6 | — | 1 | 7 |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | 1 | 2 | 3 | — | — | 6 |
| Traumatic stress disorders | D040921 | — | — | 1 | 2 | 3 | — | — | 6 |
| Mood disorders | D019964 | EFO_0004247 | F30-F39 | — | — | 5 | — | — | 5 |
| Nervous system diseases | D009422 | — | G00-G99 | 1 | — | 2 | — | 1 | 4 |
| Autistic disorder | D001321 | EFO_0003758 | F84.0 | 1 | — | 2 | — | — | 3 |
| Borderline personality disorder | D001883 | — | F60.3 | — | 3 | 1 | — | — | 3 |
Show 7 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hyperkinesis | D006948 | — | — | — | 1 | — | — | — | 1 |
| Attention deficit disorder with hyperactivity | D001289 | EFO_0003888 | F90 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Central nervous system diseases | D002493 | — | G96.9 | 1 | — | — | — | — | 1 |
| Conduct disorder | D019955 | EFO_0004216 | F91 | 1 | — | — | — | — | 1 |
| Attention deficit and disruptive behavior disorders | D019958 | — | F91.3 | 1 | — | — | — | — | 1 |
| Oppositional defiant disorder | D000096865 | — | — | 1 | — | — | — | — | 1 |
| Problem behavior | D000066553 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Aggression | D000374 | EFO_0003015 | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Brexpiprazole |
| INN | brexpiprazole |
| Description | Brexpiprazole is a N-arylpiperazine. |
| Classification | Small molecule |
| Drug class | antiulcer agents (benzimidazole derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=c1ccc2ccc(OCCCCN3CCN(c4cccc5sccc45)CC3)cc2[nH]1 |
Identifiers
| PDB | — |
| CAS-ID | 913611-97-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2105760 |
| ChEBI ID | — |
| PubChem CID | 11978813 |
| DrugBank | DB09128 |
| UNII ID | 2J3YBM1K8C (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,550 documents
View more details
Safety
Black-box Warning
Black-box warning for: Brexpiprazole, Rexulti
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
12,674 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use